Compass Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
CMPX$0.84+0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share data)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Licensing revenue | $— | $850 |
| Operating expenses: | ||
| Research and development | 55,969 | 42,342 |
| General and administrative | 16,870 | 15,133 |
| Total operating expenses | 72,839 | 57,475 |
| Loss from operations | (72,839) | (56,625) |
| Interest Income | 6,350 | 7,250 |
| Net loss | $(66,489) | $(49,375) |
| Net loss per share - basic and diluted | $(0.42) | $(0.36) |
| Basic and diluted weighted average shares outstanding | 157,695 | 137,384 |
| Other comprehensive loss: | ||
| Net loss | $(66,489) | $(49,375) |
| Unrealized gain on marketable securities | 70 | 173 |
| Comprehensive loss | $(66,419) | $(49,202) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.